PhD defence D.M. (Dora) Hammerl

Cancer immunotherapy represents a collection of effective new treatment options for a number of tumor types. Nevertheless, not all tumor types respond equally well to current immune therapies. Zooming in on breast cancer, this type of tumor is currently confronted by a number of gaps in its treatment portfolio, namely: low response rates and lack of predictive markers for immune therapies; lack of druggable targets that counteract T cell evasion; and lack of safe and effective target antigens for adoptive T cell therapies.

Due to corona, the PhD defences do not take place publicly in the usual way in the Senate Hall of the Professor Andries Querido Room. The candidates will defend their dissertation either in a small group or online.